Malignant Pleural Mesothelioma Survival Rate
Malignant pleural mesothelioma is the most shared kind of malignant mesothelioma. Many factors may be involved in calculating the survival rate for this aggressive cancer; some are better understood than others. Estimates of median survival time range from one to two years; survival depends on inner factors such as the kind and extent of spread of the mesothelioma. Only seven percent of people with this cancer survive to five years after diagnosis, but this outlook is little by little improving with some promising experimental treatments. Some people live well beyond five years from the time of diagnosis.
In general, younger age at diagnosis, absence of weight loss and limited loss of lung function are associated with chances for increased survival. Stage I mesotheliomas, which have not spread to the lymph nodes or nearby tissues and organs, also carry the best prognosis. The kind of cell the cancer is comprised of can also affect survival. The epithelioid cell kind has the best prognosis, the mixed or biphasic cell kind the next best prognosis, and the sarcomatoid cell kind the worst prognosis. The majority of malignant pleural mesotheliomas are of the epithelioid cell kind.
Because this cancer takes so long to manifest, people are usually diagnosed at an older age and with more progressive disease, potentially worsening the prognosis and the treatment options obtainable. The more aggressive the treatment, the better the outcome may be, but in situations with cancer that has spread to other parts of the body, chemotherapy may be the only different. New drugs, such as the combination of Alimta with Platinol, have been shown to enhance survival in malignant mesothelioma patients whose only option is chemotherapy. A number of experimental treatments, such as immunotherapy and biotherapy, are currently being evaluated in clinical trials.